---
layout: post
title: "Determination That ISUPREL (Isoproterenol Hydrochloride) Injection, 0.2 Milligrams per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 19:08:50 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-06311
original_published: 2024-03-26 00:00:00 +0000
significance: 8.00
---

# Determination That ISUPREL (Isoproterenol Hydrochloride) Injection, 0.2 Milligrams per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 26, 2024 00:00 UTC
**Document Number:** 2024-06311

## Summary

The Food and Drug Administration (FDA, Agency, or we) has determined that ISUPREL (isoproterenol hydrochloride) injection, 0.2 milligrams (mg)/milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for ISUPREL (isoproterenol hydrochloride) injection, 0.2 mg/mL, if all other legal and regulatory requirements are met.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/03/26/2024-06311/determination-that-isuprel-isoproterenol-hydrochloride-injection-02-milligrams-per-milliliter-was)
- API: https://www.federalregister.gov/api/v1/documents/2024-06311

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
